About bioaffinity technologies inc - BIAF
bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.
BIAF At a Glance
bioAffinity Technologies, Inc.
3300 Nacogdoches Road
San Antonio, Texas 78217
| Phone | 1-210-698-5334 | Revenue | 6.16M | |
| Industry | Medical Specialties | Net Income | -14,909,754.00 | |
| Sector | Health Technology | Employees | 57 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
BIAF Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.33 |
| Price to Book Ratio | 0.729 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.324 |
| Enterprise Value to Sales | -0.529 |
| Total Debt to Enterprise Value | -0.356 |
BIAF Efficiency
| Revenue/Employee | 108,104.544 |
| Income Per Employee | -261,574.632 |
| Receivables Turnover | 11.37 |
| Total Asset Turnover | 0.705 |
BIAF Liquidity
| Current Ratio | 2.603 |
| Quick Ratio | 2.585 |
| Cash Ratio | 2.219 |
BIAF Profitability
| Gross Margin | 23.212 |
| Operating Margin | -171.577 |
| Pretax Margin | -241.25 |
| Net Margin | -241.965 |
| Return on Assets | -170.646 |
| Return on Equity | -301.826 |
| Return on Total Capital | -176.688 |
| Return on Invested Capital | -260.129 |
BIAF Capital Structure
| Total Debt to Total Equity | 15.95 |
| Total Debt to Total Capital | 13.756 |
| Total Debt to Total Assets | 10.591 |
| Long-Term Debt to Equity | 10.676 |
| Long-Term Debt to Total Capital | 9.207 |